26 Mar 2021 17:36
26 March 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has agreed to allot in total 14,673 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options under the Company's Sharesave scheme by Derek Brady, a PDMR of the Company, at a price of 18.4p per Ordinary Share. Following this exercise, Derek Brady holds 14,673 Ordinary Shares in the Company.
Application has been made to the London Stock Exchange for the 14,673 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 1 April 2021.
After Admission, the total number of Ordinary Shares in issue will be 182,269,796 and the total number of voting rights will therefore be 182,269,796. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash / Teddy Whiley (Corporate Finance) | |
Alice Lane (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a. | Name | Derek Brady | ||||||
2 | Reason for notification |
| ||||||
a. | Position/Status | PDMR (Group Strategic Sourcing Director) | ||||||
b. | Initial notification/ Amendment | Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a. | Name | Omega Diagnostics Group Plc | ||||||
b. | LEI | 2138007U9P4BTZTYIR92 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary Shares of 4 pence each
ISIN: GB00B1VCP282 | ||||||
b. | Nature of the transaction | Acquisition of Ordinary Shares following the Exercise of Share Options | ||||||
c. | Price(s) and volume(s) | |||||||
Price(s) | Volume(s) | |||||||
18.4p | 14,673 | Purchase | ||||||
d. | Aggregated information
| As above.
| ||||||
e. | Date of the transaction | 26 March 2021 | ||||||
f. | Place of the transaction | London Stock Exchange | ||||||